{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-026058","form_type":"8-K","ticker":"INBP","cik":"0001016504","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2023-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.884263+00:00","generated_at":"2026-06-10T15:49:58.903311+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Integrated BioPharma FY2023 revenue down 9.8%; net loss of $34K vs prior year net income $3.8M","bullets":["Q4 revenue $13.0M (-2.3% YoY); operating income $79K vs $438K; net income $40K ($0.00 EPS).","FY2023 revenue $50.7M (-9.8%); operating income $120K vs $2.7M; net loss $34K ($0.00 EPS).","Diluted EPS $0.00 for both Q4 and FY; prior year $0.05 and $0.12 respectively.","Contract Manufacturing Segment contributed 95% of total revenue; two largest customers accounted for ~89%.","Warehousing/distribution business segment grew slightly as a percentage of total revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-026058","json":"https://secwatch.observer/filing/0001437749-23-026058.json","markdown":"https://secwatch.observer/filing/0001437749-23-026058.md","text":"https://secwatch.observer/filing/0001437749-23-026058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1016504/000143774923026058/0001437749-23-026058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1016504/000143774923026058/inbp20230913_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T15:49:58.903311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b8223bf5eda0813d6f6fc076a6b6a62f90c17a16","claim":"INTEGRATED BIOPHARMA INC reported fiscal year ended June 30, 2023 results: revenue $50.7 million, net income a net loss of approximately $34,000 or $0.00 per share of common stock, EPS $0.00 per share of common stock.","evidence_excerpt":"Revenues for the fiscal year ended June 30, 2023 were $50.7 million compared to $56.2 million for the fiscal year ended June 30, 2022, a decrease of $5.5 million or 9.8%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1016504/000143774923026058/0001437749-23-026058-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended June 30, 2023"},{"label":"Revenue","value":"$50.7 million"},{"label":"Net income","value":"a net loss of approximately $34,000 or $0.00 per share of common stock"},{"label":"EPS","value":"$0.00 per share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"bf8f41a3d9f5b3cc3f128702b4557965d047f12e","claim":"INTEGRATED BIOPHARMA INC reported quarter ended June 30, 2023 results: revenue $13.0 million, net income approximately $40,000 or $0.00 per share of common stock, EPS $0.00 per share of common stock.","evidence_excerpt":"Revenue for the quarter ended June 30, 2023 was $13.0 million compared to $13.3 million for the quarter ended June 30, 2022, a decrease of $0.3 million or 2.3%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1016504/000143774923026058/0001437749-23-026058-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Revenue","value":"$13.0 million"},{"label":"Net income","value":"approximately $40,000 or $0.00 per share of common stock"},{"label":"EPS","value":"$0.00 per share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}